Borghaei H, Langer CJ, Paz‐Ares L, et al. - Researchers assessed outcomes with pembrolizumab plus chemotherapy vs chemotherapy alone among patients suffering from advanced/metastatic non–small cell lung cancer (NSCLC) negative for programmed death ligand 1 (PD‐L1) (ie, a tumor proportion score < 1%) by pooling data from three randomized controlled trials (KEYNOTE‐021 cohort G, KEYNOTE‐189, and KEYNOTE‐407). There were 1,328 patients enrolled across the three trials, 444 (33.4%) of whom had PD‐L1‒negative tumors. They found that pembrolizumab plus chemotherapy conferred improved overall survival as well as progression‐free survival over chemotherapy. Overall, response, survival improvements, and a manageable safety were seen with pembrolizumab plus chemotherapy vs chemotherapy alone in patients with PD‐L1‒negative advanced/metastatic NSCLC. Pembrolizumab plus chemotherapy represents a standard‐of‐care first‐line therapy for patients suffering from advanced NSCLC, irrespective of PD‐L1 expression.